18F-piflufolastat与18F-flotufolastat在前列腺癌生化复发患者中的尿放射性及骨盆区域检出率对比
这项前瞻性多中心患者内对比研究纳入55例根治性前列腺切除术后低PSA(≤0.5 ng/mL)生化复发患者,比较18F-piflufolastat(18F-DCFPyL)与18F-flotufolastat(18F-rhPSMA-7.3)的尿放射性及检出率。结果显示18F-flotufolastat的膀胱SUVmean显著低于18F-piflufolastat,患者水平检出率分别为45.5%和27.3%。
要点
- 18F-flotufolastat膀胱SUVmean中位10.9,显著低于18F-piflufolastat的29.0(p<0.001)。
- 患者水平检出率18F-flotufolastat为45.5%(25/55),18F-piflufolastat为27.3%(15/55)。
- PSA≤0.2 ng/mL亚组中,18F-flotufolastat阳性率52.4%(11/21),18F-piflufolastat为38.1%(8/21)。
核心结论
- 患者内对比显示18F-flotufolastat的尿放射性显著低于18F-piflufolastat,可能有助于优化靠近尿路区域的图像评估。
研究设计与样本
- 前瞻性多中心患者内对比研究,纳入55例根治性前列腺切除术后生化复发(PSA≤0.5 ng/mL)且术后PSA不可测的患者。
- 患者先接受18F-piflufolastat(9 mCi)PET/CT,60分钟后显像;1–10天后在同一扫描仪接受18F-flotufolastat(8 mCi)PET/CT,60分钟后显像。
- 主要终点为两种药物间尿放射性(SUVmean)差异,次要终点为患者水平和区域水平检出率,由两名盲法读者评估,分歧由第三读者裁决。
主要发现
- 膀胱SUVmean中位数18F-piflufolastat为29.0(四分位距18.9–40.8),18F-flotufolastat为10.9(四分位距6.0–18.5),p<0.001(Wilcoxon符号秩检验)。
- 患者水平检出率(多数读片)18F-piflufolastat为27.3%(15/55),18F-flotufolastat为45.5%(25/55)。
- 区域水平检出率:前列腺床18F-piflufolastat 10.9%(6/55)、18F-flotufolastat 18.2%(10/55);盆腔淋巴结14.5%(8/55)和16.4%(9/55);盆腔外部位7.3%(4/55)和21.8%(12/55)。
- PSA≤0.2 ng/mL患者中,18F-piflufolastat和18F-flotufolastat阳性扫描分别为38.1%(8/21)和52.4%(11/21)。
临床怎么用
- 对于根治性前列腺切除术后低PSA生化复发患者,18F-flotufolastat因尿放射性较低,可能更利于评估靠近尿路的病灶。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This prospective, multicentre, intra-patient comparator study assessed urinary radioactivity, and patient-level and region-level detection rates (DR) with PSMA-PET radiopharmaceuticals, 18F-piflufolastat (18F-DCFPyL) and 18F-flotufolastat (18F-rhPSMA-7.3) in patients with biochemical recurrence (BCR) of prostate cancer to evaluate the hypothesis that lower urinary radioactivity is observed with 18F-flotufolastat. METHODS: Patients with low PSA (≤0.5 ng/mL) BCR ≥6 months post-prostatectomy with undetectable PSA post-surgery, scheduled for standard-of-care 18F-piflufolastat PSMA-PET were enrolled. Patients underwent PET/CT 60 minutes post-18F-piflufolastat (9 mCi) administration, and a second PET/CT on the same scanner 1–10 days later, 60 minutes post-18F-flotufolastat (8 mCi) administration. The primary endpoint was the difference in urinary radioactivity (SUVmean) between the radiopharmaceuticals. Secondary endpoints included patient-level and region-level DR for each radiopharmaceutical, assessed by two blinded readers (a third resolved disagreements, allowing majority reads). RESULTS: Fifty-five evaluable patients (mean PSA, 0.28 ng/mL) were enrolled. Median bladder SUVmean was significantly higher with 18F-piflufolastat (29.0; interquartile range, 18.9–40.8) than 18F-flotufolastat (10.9; interquartile range, 6.0–18.5; p < 0.001 [Wilcoxon signed-rank test]). Majority read patient-level DR were 27.3% (15/55) for 18F-piflufolastat and 45.5% (25/55) for 18F-flotufolastat. Region-level DR for 18F-piflufolastat and 18F-flotufolastat, were 10.9% (6/55) and 18.2% (10/55) in the prostate bed, 14.5% (8/55) and 16.4% (9/55) in pelvic lymph nodes, and 7.3% (4/55) and 21.8% (12/55) in extra-pelvic sites. Among patients with PSA ≤0.2 ng/mL, 38.1% (8/21) and 52.4% (11/21) had positive 18F-piflufolastat and 18F-flotufolastat scans, respectively. CONCLUSIONS: This intra-patient comparator shows 18F-flotufolastat has significantly lower urinary radioactivity than 18F-piflufolastat, which may help to optimise image assessment in regions close to the urinary tract. CLINICAL TRIAL REGISTRATION: Trial registration, clinicaltrials.gov: NCT06604442. Registered September 2024.
引用
- Nordquist LT, Andrews JR, Kuo PH, et al. An intra-patient contemporaneous comparison of 18F-piflufolastat and 18F-flotufolastat urinary radioactivity and pelvic region detection rates in men with low PSA biochemical recurrence of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2026. PMID: 41729277. doi:10.1007/s00259-025-07732-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。